Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC)

被引：0
|
作者：
Merle, Philippe
Peron, Jean-Marie
Le Malicot, Karine
Guarssifi, Meriem
Aparicio, Thomas
Bourgeois, Vincent
Assenat, Eric
Blanc, Jean-Frederic
Bouattour, Mohamed
Touchefeu, Yann
Akouz, Faiza Khemissa
Nguyen-Khac, Eric
Bronowicki, Jean-Pierre
Girot, Paul
Lam, You Heng
Bolliet, Marion
Adhoute, Xavier
Edeline, Julien
Nault, Jean-Charles
Phelip, Jean Marc
机构：
[1] Croix Rousse Hosp, Hepatol Unit, Lyon, France
[2] Hop Purpan, Serv Hepatogastroenterol, Toulouse, France
[3] INSERM, U1231, FFCD, Dijon, France
[4] FFCD, Dijon, France
[5] Hop St Louis, AP HP, Dept Gastroenterol, Paris, France
[6] Hop Duchenne, Digest Oncol, Boulogne Sur Mer, France
[7] St Eloi Univ Hosp, Montpellier, France
[8] CHU Bordeaux, Grp Hosp Haut Leveque, Bordeaux, France
[9] Hop Beaujon, AP HP, Clichy, France
[10] CHU Nantes, Dept Hepatogastroenterol, Nantes, France
[11] Hop St Jean, Perpignan, France
[12] CHU Amiens, Amiens, France
[13] Hop Brabois Adulte Nancy, Serv Hepatogastroenterol, Nancy, France
[14] Eugene Marquis Ctr, Dept Med Oncol, Rennes, France
[15] Hop Univ Paris Seine St Denis, Hop Jean Verdier, Bondy, France
[16] Univ Hosp St Etienne, St Priest En Jarez, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16195
引用
收藏
页数：1
相关论文
共 12 条
  • [1] Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial
    Merle, Philippe
    Blanc, Jean-Frederic
    Edeline, Julien
    Le Malicot, Karine
    Allaire, Manon
    Assenat, Eric
    Guarssifi, Meriem
    Bouattour, Mohamed
    Peron, Jean-Marie
    Laurent-Puig, Pierre
    Levrero, Massimo
    Costentin, Charlotte
    Guiu, Boris
    Sokol, Harry
    Tougeron, David
    Aparicio, Thomas
    Nault, Jean-Charles
    Phelip, Jean-Marc
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (04) : 464 - 470
  • [2] Safety and efficacy preliminary analysis of first-line systemic therapy with atezolizumab plus bevacizumab in Spanish patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: phase IIIb ATHECA trial
    Reig, Maria
    Luque, Natalia
    Lledo, Jose Luis
    Matilla, Ana
    Montero, Jose Luis
    Pazo-Cid, Roberto
    Varela, Maria
    Borras, Mar
    Ordonez, Jose-Manuel
    Argemi, Josep Maria
    Bruix, Jordi
    Gomez-Martin, Carlos
    Perez-Lopez, Raquel
    Rimola, Jordi
    Sangro, Bruno
    Sastre, Javier
    JOURNAL OF HEPATOLOGY, 2024, 80 : S455 - S456
  • [3] IMbrave150: exploratory efficacy and safety results of atezolizumab plus bevacizumab vs sorafenib in patients (pts) with unresectable hepatocellular carcinoma (HCC) who had prior locoregional therapy (LRT)
    Qian, Yuquan
    Liu, Baojiang
    Weiss, Christel
    Zhu, Xu
    Teufel, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 79 - 79
  • [4] Atezolizumab plus Bevacizumab in second or further line therapy in patients with advanced stage hepatocellular carcinoma (HCC): data on efficacy and safety from a multicenter real-life cohort
    Sinner, Friedrich
    Pinter, Matthias
    Scheiner, Bernhard
    Ettrich, Thomas J.
    Sturm, Niklas
    Gonzalez-Carmona, Maria Angeles
    Waidmann, Oliver
    Finkelmeier, Fabian
    Himmelsbach, Vera
    De Toni, Enrico
    Ben Khaled, Najib
    Mohr, Raphael
    Fruendt, Thorben
    Kueting, Fabian
    Van Boemmel, Florian
    Lieb, Sabine
    Krug, Sebastian
    Bettinger, Dominik
    Schultheiss, Michael
    Jochheim, Leonie
    Best, Jan
    Mueller, Christian
    Venerito, Marino
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 84 - 85
  • [5] Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ plus BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
    Monzon, M. E. Reig
    Caro, N. Luque
    Bruix, J.
    Martin, C. Gomez
    Sangro, B.
    Varela, J. Sastre
    Tres, J. M. Ordonez
    Argemi, J.
    Lopez, R. Perez
    Candela, M. P. Torres
    Lledo-Navarro, J. L.
    Pena, A. M. Matilla
    Montero, J-L.
    Cid, R. A. Pazo
    Varela, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S606 - S607
  • [6] A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo plus bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh class B cirrhosis: CHALLENGE trial final results.
    Ikeda, Masafumi
    Terashima, Takeshi
    Yamashita, Tatsuya
    Okusaka, Takuji
    Imaoka, Hiroshi
    Kawaoka, Tomokazu
    Kobayashi, Satoshi
    Ogasawara, Sadahisa
    Hiraoka, Atsushi
    Nakano, Masahito
    Nagashima, Fumio
    Sugimoto, Rie
    Moriguchi, Michihisa
    Inaba, Yoshitaka
    Shinoda, Satoru
    Ueno, Makoto
    Kato, Naoya
    Kudo, Masatoshi
    Furuse, Junji
    Nagano, Hiroaki
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [7] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
    Yopp, A.
    Kudo, M.
    Chen, M.
    Cheng, A-L.
    Kaseb, A. O.
    Lee, H. C.
    Qin, S.
    Cha, E.
    Hack, S. P.
    Lian, Q.
    Spahn, J.
    Wu, C.
    Chow, P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230
  • [8] A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data
    Petrini, I.
    Lencioni, M.
    Ricasoli, M.
    Iannopollo, M.
    Orlandini, C.
    Oliveri, F.
    Filipponi, F.
    Bartolozzi, C.
    Del Tacca, M.
    Ricci, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] SAFETY AND ANTITUMOR ACTIVITY OF NGR-HTNF, A SELECTIVE VASCULAR TARGETING AGENT (VTA), ADMINISTERED AT LOW DOSE IN PRE-TREATED PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS OF A PHASE II TRIAL
    Citterio, G.
    Santoro, A.
    Pressiani, T.
    Scalamogna, R.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 178 - 178
  • [10] IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS (PTS) WITH MAIN TRUNK AND/OR CONTRALATERAL PORTAL VEIN INVASION (VP4) TREATED WITH ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN A PH III STUDY
    Finn, Richard S.
    Breder, Valeriy
    Vogel, Arndt
    Merle, Philippe
    Galle, Peter R.
    Zhu, Andrew
    Cheng, Ann-Lii
    Feng, Yin-Hsun
    Li, Daneng
    Gaillard, Vincent E.
    Li, Lindong
    Nicholas, Alan
    Lencioni, Riccardo
    GASTROENTEROLOGY, 2024, 166 (05) : S1738 - S1738
12